Table 1. Clinical, histological, molecular data of HCC in training cohort.
| Variables | Categories | Total(n = 221) | OS | RFS | ||
|---|---|---|---|---|---|---|
| HR | p-value | HR | p-value | |||
| Age | < = 56 | 112(51%) | 0.917 | 0.256 | ||
| >56 | 109(49%) | 1.02(0.67–1.56) | 1.23(0.86–1.76) | |||
| Gender | female | 30(14%) | 0.153 | 0.019* | ||
| male | 191(86%) | 1.7(0.82–3.52) | 2.17(1.13–4.14) | |||
| NA | 3(1%) | |||||
| AFP | < = 300ng/ml | 118(53%) | 0.017* | 0.159 | ||
| >300ng/ml | 100(45%) | 1.68(1.1–2.58) | 1.25(0.82–1.91) | |||
| ALT | < = 50U/L | 130(59%) | 0.726 | 0.23 | ||
| >50U/L | 91(41%) | 1.08(0.7–1.66) | 1.25(0.87–1.78) | |||
| NA | 1(0%) | |||||
| Size | < = 5cm | 140(63%) | 0.002* | 0.067 | ||
| >5cm | 80(36%) | 1.94(1.26–2.99) | 1.41(0.98–2.04) | |||
| Multinodular | No | 176(80%) | 0.057 | 0.428 | ||
| Yes | 45(20%) | 1.59(0.99–2.57) | 1.19(0.77–1.84) | |||
| cirrhosis | No | 18(8%) | 0.032* | 0.062 | ||
| Yes | 203(92%) | 4.62(1.14–18.8) | 2.18(0.96–4.97) | |||
| NA | 2(1%) | |||||
| TNM | I | 93(42%) | <0.001** | <0.001** | ||
| II | 77(35%) | 2.08(1.21–3.58) | 1.97(1.29–3.01) | |||
| III | 49(22%) | 5.05(2.91–8.79) | 3.14(1.97–5.01) | |||
| NA | 2(1%) | |||||
| BCLC | 0-A | 168(76%) | <0.001** | <0.001** | ||
| B-C | 51(23%) | 3.63(2.33–5.65) | 2.78(1.88–4.11) | |||
| NA | 2(1%) | |||||
| CLIP | 0 | 97(44%) | <0.001** | 0.0017** | ||
| 1 | 74(33%) | 1.49(0.86–2.56) | 2.21(1.42–3.43) | |||
| 2–5 | 48(22%) | 3.75(2.24–6.3) | 1.25(0.82–1.91) | |||
In univariate analysis, the three staging systems, TNM, BCLC and CLIP, were most significantly associated with overall survival and recurrence-free survival. AFP, a-fetoprotein; ALT, alanine transferase; Prognostic staging system: TNM, Tumor Node Metastasis; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer Liver Italian Program. OS, overall survival; RFS, recurrence-free survival; HR: hazard ratio.
**P-value <0.01;
*P-value <0.05.